United Therapeutics (UTHR) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

United Therapeutics

NasdaqGS•Healthcare•Drug Manufacturers - Specialty & Generic

$487.61-2.63(-0.01%)Pre-market

Market Cap

$21.07B

P/E

16.1x

P/S

6.7x

P/B

3.3x

United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. Further, it provides preclinical products, including EVLP/CLES, for lung transplant; UKidney, UHeart, UThymoKidney, a development-stage gene-edited porcine kidneys and hearts for xenotransplantation; ULobe, for allogeneic regenerative medicine; ULung, for autologous regenerative medicine; IVIVA Kidney, for autologous regenerative medicine; miroliver, for allogeneic regenerative medicine; and mirokidney, for allogeneic regenerative medicine. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.

How this company scores

GoodMetricSide Score: 76/100

Strongest: Profitability (25/25); weakest: Balance Sheet & Red Flags (15/25).

Profitability25/25

Growth17/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality19/25

Strengths

Strong marginsHigh ROEInterest easily coveredConsistent free cash flow

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 16.1x5y range 10.2x – 26.8x

Currently near its 20-quarter median.

P/S · 6.7x5y range 4.2x – 8.1x

Currently above its 20-quarter median.

P/B · 3.3x5y range 1.7x – 4.3x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

Some Concerns

Margin Pressure

Watch

Operating margins declined 5.6% — watch for continued compression, which may signal competitive or cost pressure.

Earnings Quality

Watch

FCF/Net Income has dropped below 0.7x in 3 quarters — monitor for earnings quality deterioration.

Price & Volume

Market Cap $21.07B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $3.15B
Q. Revenue: $783.30M
TTM EBITDA: $1.54B
TTM Op. Income: $1.40B
Q. Op. Income: $330.80M
TTM Net Income: $1.31B
Q. Net Income: $333.00M
EPS: $7.82
Shares Out.: $42.60M

$3.15B in TTM revenue grew 2.5% YoY, reaching $783.30M last quarter. TTM EBITDA of $1.54B and TTM operating income of $1.40B show growth is flowing through to the bottom line. TTM net income of $1.31B means revenue is converting into profit. Across the last 8 quarters, TTM revenue has fallen for 2 consecutive quarters — a weakening trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 87.3%
EBITDA Margin: 45.3%
Op. Margin: 42.2%
Net Margin: 42.5%

Op. margin of 42.2% is down 3.4% YoY — costs are rising relative to revenue. Net margin at 42.5% and gross margin of 87.3% show how much of each revenue dollar survives to profit. Over the past year, operating margin is down 7% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 16.1x
P/S Ratio: 6.7x
P/B Ratio: 3.3x

At 16.1x P/E, the stock trades within typical market levels. P/S of 6.7x and P/B of 3.3x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Over the past year, P/E is up 54% — an improving trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $7.22B
Cash: $1.80B
Long-Term Debt: N/A
Book Value: $6.40B
D/E Ratio: N/A
Debt/EBITDA: 0.0

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $313.60M
TTM Free Cash Flow: $1.09B
FCF Margin: 34.6%
FCF / Net Income: 0.8

TTM FCF of $1.09B on $313.60M in operating cash flow. The FCF / Net Income ratio of 0.8x means free cash flow covers net income — earnings are backed by cash. Over the past year, free cash flow is up 2% — an improving trend.